Version 13 2022-04-18, 18:39Version 13 2022-04-18, 18:39
Version 12 2021-07-15, 21:20Version 12 2021-07-15, 21:20
Version 11 2021-04-26, 13:59Version 11 2021-04-26, 13:59
Version 10 2021-03-15, 16:47Version 10 2021-03-15, 16:47
Version 9 2021-02-15, 14:43Version 9 2021-02-15, 14:43
Version 8 2021-01-19, 19:34Version 8 2021-01-19, 19:34
Version 7 2021-01-18, 17:33Version 7 2021-01-18, 17:33
Version 6 2021-01-11, 19:30Version 6 2021-01-11, 19:30
Version 5 2021-01-11, 17:44Version 5 2021-01-11, 17:44
Version 4 2020-12-07, 14:17Version 4 2020-12-07, 14:17
Version 3 2020-12-07, 14:11Version 3 2020-12-07, 14:11
Version 2 2020-11-09, 20:25Version 2 2020-11-09, 20:25
Version 1 2020-11-06, 03:03Version 1 2020-11-06, 03:03
online resource
posted on 2021-04-26, 13:59authored byUSG COVID-19 Response Team / Coronavirus Prevention Network (CoVPN) Biostatistics Team, Peter B. Gilbert, Youyi Fong, David Benkeser, Jessica Andriesen, Bhavesh BorateBhavesh Borate, Marco Carone, Lindsay N. CarppLindsay N. Carpp, Ivan Diaz, Michael P. Fay, Andrew Fiore-GartlandAndrew Fiore-Gartland, Nima S. Hejazi, Ying Huang, Yunda Huang, Ollivier Hyrien, Holly E. Janes, Michal Juraska, Kendrick Li, Alex Luedtke, Martha Nason, April K. Randhawa, Lars van der Laan, Brian Williamson, Wenbo Zhang, Dean Follmann
This Statistical Analysis Plan (SAP) describes the statistical analysis of antibody markers measured at a key time point post last vaccination as correlates of risk and as various types of correlates of protection against primary and secondary endpoints in COVID-19 Prevention Network (CoVPN) COVID-19 vaccine efficacy (VE) trials.
Funding
National Institute of Allergy and Infectious Diseases (NIAID) UM1AI068635
National Institute of Allergy and Infectious Diseases (NIAID) R37AI054165